Floatz logo

Therapeutic Asset Ratings

13,145 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Nucleo Cmp Forte
Trigeminal Neuralgia
Karbala UniversityP2B (57)
Ociperlimab
Hepatocellular Carcinoma
BeiGeneP2B (57)
Odetiglucan
Breast Cancer
HiberCell, Inc.P2B (57)
Oditrasertib
Amyotrophic Lateral Sclerosis
SanofiP2B (57)
Olaparib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)P2B (57)
Olaparib
Cutaneous Melanoma
Dana-Farber Cancer InstituteP2B (57)
Olaparib
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)P2B (57)
Olaparib
Urothelial Carcinoma
Rahul AggarwalP2B (57)
Olaparib
Malignant Germ Cell Tumor
National Cancer Institute (NCI)P2B (57)
Olaparib
Glioma
University Health Network, TorontoP2B (57)
Olaparib
Myelodysplastic Syndrome
National Cancer Institute (NCI)P2B (57)
Olaparib
Uterine Corpus Cancer
National Cancer Institute (NCI)P2B (57)
Oleogel-S10
Breast Carcinoma
Memorial Sloan Kettering Cancer CenterP2B (57)
Olutasidenib
Myelodysplastic Syndrome
National Cancer Institute (NCI)P2B (57)
OTL-38
Prostate Cancer
Indiana UniversityP2B (57)
Oxaliplatin
Endometrial Cancer
Merck Sharp & Dohme LLCP2B (57)
Oxaliplatin
Rectal Disorder
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2B (57)
Oxaliplatin
Urinary Bladder Neoplasm
Merck Sharp & Dohme LLCP2B (57)
Oxaliplatin
Uterine Cervix Neoplasm
Merck Sharp & Dohme LLCP2B (57)
Oxodotreotide
Pancreatic Endocrine Carcinoma
Alliance for Clinical Trials in OncologyP2B (57)
Oxodotreotide
Prostate Cancer
National Cancer Institute (NCI)P2B (57)
Oxybutynin
Prostate Carcinoma
Alliance for Clinical Trials in OncologyP2B (57)
Palbociclib
Cancer
Bristol-Myers SquibbP2B (57)
Palbociclib
Langerhans Cell Histiocytosis
National Cancer Institute (NCI)P2B (57)
Palbociclib
Fallopian Tube Carcinoma
National Cancer Institute (NCI)P2B (57)
Showing 3326 to 3350 of 13,145 assets
PreviousPage 134 of 526Next